Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KRYS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Topical Beremagene Geperpavec | Dystrophic Epidermolysis Bullosa | Phase 3 · NCT04491604 | Completed |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Dystrophic Epidermolysis Bullosa | Phase 3 · NCT04917874 | Completed |
| KB803 | Dystrophic Epidermolysis Bullosa | Phase 3 · NCT07016750 | Recruiting |
| Cytotoxic Chemotherapeutic Agent | Lung Cancer, Non-small Cell | Phase 1/2 · NCT06228326 | Recruiting |
| KB801 | Neurotrophic Keratitis | Phase 1/2 · NCT06999733 | Recruiting |
| Oncolytic HSV-1 Expressing IL-2 and IL-12 KB707 | Cancer | Phase 1/2 · NCT05970497 | Recruiting |
| KB304 | Wrinkles in Decolletage | Phase 1/2 · NCT06724900 | Active not recruiting |
| KB105 | Autosomal Recessive Ichthyosis | Phase 2 · NCT05735158 | Unknown |
| KB408 (Nebulization) | Alpha 1-Antitrypsin Deficiency | Phase 1 · NCT06049082 | Recruiting |
| KB407 (Nebulization) | Cystic Fibrosis | Phase 1 · NCT05504837 | Recruiting |
| KB301 | Skin Roughness | Phase 1 · NCT04540900 | Active not recruiting |
| KB111 | Hailey Hailey Disease | Early Phase 1 · NCT07717346 | Recruiting |
Also used in these trials (approved or third-party drugs, not KRYS's own candidates): Pembrolizumab, Nivolumab And Relatlimab-Rmbw, Docetaxel Anhydrous.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
KRYS holds $911.9M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KRYS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BlackRock, Inc. | Institution (13G, 5%+) | 3,427,645 | 11.57% | 2026-09-30 |
| Krish S Krishnan President and CEO, Director, 10% owner · +63,389 options |
Insider | 1,565,253 | 5.28% | 2026-09-04 |
| Suma Krishnan President, R&D, Director, 10% owner · +93,892 options |
Insider | 1,493,155 | 5.04% | 2026-09-04 |
| Daniel Janney Director · +6,658 options |
Insider | 73,293 | 0.25% | 2026-02-27 |
| Dino A Rossi Director · +6,658 options |
Insider | 46,500 | 0.16% | 2026-11-12 |
| Kathryn Romano Chief Accounting Officer · +41,517 options |
Insider | 22,366 | 0.08% | 2026-02-27 |
| Laurent Louis Jean Goux EVP, Head of International |
Insider | 919 | 0.00% | 2026-03-01 |
Share count 29,633,472 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KRYS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →